Approved Study Database
| Ref. No. | Scientific Title | Principal investigator |
|---|---|---|
| 2013.115 | An Open Label, Phase 2a, Single-Arm Study of the Antifibrotic Activity of FG-3019 in Subjects with Advanced Liver Fibrosis due to Chronic Hepatitis C Infection (HCV) | Prof Chan Lik Yuen Henry |
| 2013.117 | An Open Label, Phase 2a, Single-Arm Study of the Antifibrotic Activity of FG-3019 in Subjects with Advanced Liver Fibrosis due to Chronic Hepatitis C Infection (HCV) | Dr. Hui Aric Josun |
| 2022.174 | AN OPEN LABEL, RANDOMISED, PHASE 2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MTL-CEBPA ADMINISTERED IN COMBINATION WITH SORAFENIB OR SORAFENIB ALONE, IN TKI NAÏVE PARTICIPANTS WITH PREVIOUSLY TREATED ADVANCED HEPATOCELLULAR CARCINOMA (HCC) AND HEPATITIS B OR HEPATITIS C VIRUS (OUTREACH2) |
Prof. CHAN Stephen Lam 陳林 |
| 2014.409 | An Open Label, Randomized Phase 3 Clinical Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Platinum-refractory Squamous Cell Carcinoma of the Head and Neck (SCCHN) | Prof. CHAN Anthony Tak Cheung |
| 2010.600 | An Open Label, Randomized, Cross-Over Study to Investigate the Single Dose Bioequivalence of Lamotrigine Dispersible/Chewable Tablets (5mg) Compared to Lamotrigine Compressed/Standard Tablets (25mg) in Chinese Healthy Male Subjects. | Professor Tomlinson Brian |
| 2007.038 | An Open Label, Randomized, Multi-Center, Parallel Group Study to Demonstrate Treatment of Anemia Using Intravenous Injections of RO0503821 in Patients with Chronic Kidney Disease Who are on Dialysis | Dr. Li KT Philip |
| 2003.190 | An Open Label, Randomized, Multicenter, Phase II Study to Determine Hemoglobin Dose Response, Safety and Pharmacokinetic Profile of Ro 50-3821 Given Subcutaneously Once Weekly or Once Every 3 Weeks to Anemic Patients with Stage IIIB or IV Non-Small Cell Lung Carcinoma Receiving Antineoplastic Therapy | Prof. Mok S.K. Tony |
| 2005.415 | An Open Label, Randomized, Parallel Group, Multicentre, Phase III Study to Assess Efficacy, Safety and Tolerability of Gefitinib (IRESSA | Prof. Mok SK Tony |
| 2018.362 | An open uncontrolled trial of Imagery Rescripting for Depression |
Ms. LEE Sze Wai 李思慧 |
| 2004.371 | An Open-Label 7-Day Study to Determine the Influence of CYP2C19 Genotype on the Pharmacokinetics of RO2052349 in Patients with Type 2 Diabetes Mellitus in the Asia-Pacific Region | Prof. Brian Tomlinson |
| 2013.430 | AN OPEN-LABEL BOSUTINIB TREATMENT EXTENSION STUDY FOR SUBJECTS WITH CHRONIC MYELOID LEUKEMIA (CML) WHO HAVE PREVIOUSLY PARTICIPATED IN BOSUTINIB STUDIES B1871006 OR B1871008 | Dr. WONG Raymond Siu Ming |
| 2007.371 | An Open-Label Clinical Trial to Evaluate Efficacy and Safety of Peginterferon Alfa-2a (PEGASYS_) Plus Entecavir (Baraclude) combination Therapy in HBeAg Positive Chronic Hepatitis B (CHB) Patients | Prof. Sung JY Joseph |
| 2006.367 | An Open-Label Expanded Access Study of Lapatinib and Capecitabine Therapy in Subjects with ErbB2 Overexpressing Locally Advanced or Metastatic Breast Cancer | Dr. Ho Wing Ming |
| 2008.382 | An Open-Label Extension Phase of the Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Studies to Evaluate the Efficacy and Safety of E2007 (perampanel) Given as Adjunctive Therapy in Subjects with Refractory Partial Seizures | Dr Kwan Patrick |
| 2003.293 | An Open-Label Extension Study to Assess the Safety and Tolerability of a 25mg Dose of SCH 420814 as Monotherapy in Subjects with Early Parkinson | Prof. Wong Ka Sing Lawrence |
| 2011.599 | An Open-Label Extension Study to Assess the Safety of GSK1605786A in Subjects with Crohn | Dr Ng Siew Chien |
| 2021.535 | An Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of Marstacimab Prophylaxis in Severe (Coagulation Factor Activity <1%) Hemophilia A Participants With or Without Inhibitors or Moderately Severe to Severe Hemophilia B Participants (Coagulation Factor Activity ≤2%) With or Without Inhibitors | Prof. Li Chi Kong |
| 2019.481 | AN OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF REGN3918 IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA | Dr. WONG Raymond Siu Ming |
| 2021.567 | An open-label extension study to investigate the long-term safety, tolerability, and efficacy of rozanolixizumab in study participants with persistent or chronic primary immune thrombocytopenia (ITP) |
Dr. WONG Raymond Siu Ming 王紹明 |
| 2002.411 | An Open-Label Extension Trial to Assess The Safety of Galantamine HBr in the Treatment of Vascular Dementia Revised : cre-2002.216-t, cre-2002.124-t | Prof. Wong Ka Sing Lawrence |
| 2005.300 | An Open-Label Follow-up Trial of the Efficacy and Safety of Chronic Administration of the Fixed Dose Combination of Telmisartan 80mg + Hydrochlorothiazide 25mg tablets Alone or in Combination with Other Antihypertensive Medications in Patients with Hypertension | Prof. Kong Pik Shan Alice |
| 2011.562 | An Open-Label Long-term Safety Extension Trial for Subjects with Systemic Lupus Erythematosus Who Have Completed Protocol AN-SLE3321 (PEARL-SC) | Professor Tam Lai-Shan |
| 2011.028 | An open-label multi-center study of erlotinib (Tarceva®) as first line therapy until and beyond RECIST progression in NSCLC patients who harbor EGFR mutations | Prof. MOK Tony Shu Kam |
| 2010.158 | An Open-Label Multicenter Extension Study to Determine Long Term Safety and Efficacy of Pregabalin (Lyrica) as Monotherapy in Patients with Partial Seizures | Dr. Kwan Patrick |
| 2005.197 | An Open-Label Multicenter Randomized Phase 3 Study Comparing the Combination of DOXIL_/CAELYX_ and YONDELIS | Prof. Yeo Winnie |
| 2007.247 | An Open-Label Multicenter Study Administering Lapatinib and Capecitabine (Xeloda) in Women with Advanced or Metastatic Breast Cancer | Prof. Yeo Winnie |
| 2024.724 | An Open-Label Phase 1/2 Study of WGI-0301 Plus Sorafenib in Patients with Advanced Hepatocellular Carcinoma as Second Line Therapy |
Prof. CHAN Stephen Lam 陳林 |
| 2023.312 | An Open-Label Phase 1b Study Evaluating the Safety, Tolerability, Immunogenicity and Antiviral Activity of Multiple Doses of CLB-3000 in Subjects with Chronic Hepatitis B | Prof. WONG Grace |
| 2007.241 | An Open-Label Phase I/II Study to Assess the Safety and Immunogenicity of Two Doses of a Vero Cell-Derived, Whole Virus Clade 2 H5N1 Influenza Vaccine in Healthy Volunteers Aged 21 to 45 Years | Prof. Hui SC David |
| 2016.165 | An open-label phase II study of pembrolizumab in East Asian patients with advanced/metastatic acral lentiginous melanoma |
Dr. LOONG Herbert 龍浩鋒 |
| 2010.457 | An Open-label Phase Ii Study of TK1258 as Neo-adjuvant Therapy in Patient with Muscle-invasive Bladder Cancer | Dr Chan Shu Yin Eddie |
| 2002.394 | An Open-Label Phase IIa Trial of Evaluating the Safety and Efficacy of EPO906 as Therapy in Patients with Advanced Local or Metastatic Gastric Cancer | Prof. Yeo Winnie |
| 2018.444 | An open-label pilot study of fecal microbiota transplant (FMT) to induce weight loss in obese subjects |
Prof. NG Siew Chien 黃秀娟教授 |
| 2007.242 | An Open-Label Prospective Trial to Explore the Tolerability, Safety and Efficacy of Flexibly Dosed Paliperidone ER in Subjects with Schizophrenia | Dr. Chung Wai Sau Dicky |
| 2021.134 | An open-label randomized controlled trial on convalescent plasma for treatment of severe COVID-19 infection |
Dr. LUI Grace C.Y. 雷頌恩 |
| 2015.607 | An Open-label Randomized Multinational Phase 3 Trial of Nivolumab versus Docetaxel in Previously Treated Subjects with Advanced or Metastatic Non-small Cell Lung Cancer |
Prof. MOK Tony Shu Kam 莫樹錦 |
| 2003.230 | An Open-Label Randomized Phase III Study of Intermittent Oral Capecitabine in Combination with Intravenous Oxaliplatin (Q3W) ("XELOX") versus Bolus and Continuous Infusion Fluorouracil/Intravenous Leucovorin with Intravenous Oxaliplatin (Q2W) ("FOLFOX-4") as First-Line Treatment for Patients with Metastatic Colorectal Cancer | Prof. Chan Tak Cheung Anthony |
| 2019.704 | An Open-Label Study in Adolescent and Adult Severe (Coagulation Factor Activity <1%) Hemophilia A Participants With or Without Inhibitors or Moderately Severe to Severe Hemophilia B Participants (Coagulation Factor Activity ≤2%) With or Without Inhibitors Comparing Standard Treatment to PF-06741086 Prophylaxis |
Prof. LI Chi Kong 李志光教授 |
| 2017.568 | An Open-Label Study of Brentuximab Vedotin+Adriamycin, Vinblastine, and Dacarbazine in Pediatric Patients With Advanced Stage Newly Diagnosed Hodgkin Lymphoma |
Prof. LI Chi Kong 李志光教授 |
| 2007.361 | An open-label study to evaluate the safety and efficacy of IMATINIB with chemotherapy in pediatric patients with Ph+/BCR-ABL+ acute lymphoblastic leukemia (Ph+ALL) | Dr. LI Chi Kong |
| 2012.034 | An Open-label study to investigate Deep Brain Stimulation over ventral capsule/ventral striatum area in the treatment of Resistant Obsessive Compulsive Disorder | Prof. POON Wai Sang |
| 2010.255 | An Open-label study to investigate Deep Brain Stimulation over verntal capsule/ventral striatum area in the treatment of Treatment Resistant Major Depressive Disorder | Prof. Wing Yun Kwok |
| 2012.357 | An open-label trial of 48-week peginterferon alfa-2a (PEGASYS) to assess the sustained response of chronic hepatitis B patients with HBeAg seroconversion on nucleot(s)ide analogue therapy | Prof. WONG Grace Lai Hung |
| 2013.016 | An open-label trial of 48-week peginterferon alfa-2a (PEGASYS) to assess the sustained response of chronic hepatitis B patients with HBeAg seroconversion on nucleot(s)ide analogue therapy | Dr. Chan Kam Hon |
| 2012.539 | An open-label trial of 48-week peginterferon alfa-2a (PGEASYS) to assess the sustained response of chroinc hepatitis B patients with HBeAg seroconversion on nucleot(s)ide analogue therapy | Dr. HUI Aric Josun |
| 2002.459 | An Open-label, Long-term, Flexible-dose Study of Safety, Tolerability, and Therapeutic Response of PNU-95666E in Patients with Parkinson's Disease | Prof. Wong Ka Sing Lawrence |
| 2025.180 | An Open-label, Multi-center Phase II Study of Durvalumab and Tremelimumab with Lenvatinib as First-line Treatment in Patients with Unresectable Hepatocellular Carcinoma | Prof. CHAN Stephen Lam |
| 2019.684 | An open-label, multi-center rollover protocol for continued characterization of safety and tolerability for subjects who have participated in a Novartis-sponsored spartalizumab study as single agent or in combination with other study treatments |
Prof. MA Brigette Buig Yue 馬碧如教授 |
| 2019.453 | An open-label, multi-center, Phase IV, roll-over study in patients with ALK positive malignancies who have completed a prior Novartis-sponsored ceritinib (LDK378) study and are judged by the investigator to benefit from continued treatment with ceritinib |
Dr. LOONG Herbert Ho Fung 龍浩鋒醫生 |
| 2012.451 | An Open-Label, Multi-Center, Single Arm Study to Evaluate the Safety and Tolerability of Intravenous Zanamivir in the Treatment of Hospitalized Adult, Adolescent and Pediatric Subjects with Confirmed Influenza Infection | Professor Leung Ting Fan |
Page 62 of 289.

